← All trials
NCT04322123
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2020
- Primary completion
- Aug 30, 2020
- Completion date
- Aug 30, 2020
- First posted
- Mar 26, 2020
- Last posted
- Apr 13, 2020
- Enrollment
- 630
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hospital do CoracaoLead sponsor
- EMS S/ACollaborator
- Albert Einstein Israelite HospitalCollaborator
- Albert Einstein Israelite HospitalOverall official - principal investigator
- Hospital Sirio-LibanesCollaborator
- Brazilian Research In Intensive Care NetworkCollaborator
- Hospital do CoraçãoStudy chair
- Hospital do CoraçãoOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.